- Japan
- /
- Healthcare Services
- /
- TSE:9273
It's A Story Of Risk Vs Reward With Koa Shoji Holdings Co.,Ltd. (TSE:9273)
Koa Shoji Holdings Co.,Ltd.'s (TSE:9273) price-to-earnings (or "P/E") ratio of 9.5x might make it look like a buy right now compared to the market in Japan, where around half of the companies have P/E ratios above 14x and even P/E's above 21x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E.
With earnings growth that's superior to most other companies of late, Koa Shoji HoldingsLtd has been doing relatively well. One possibility is that the P/E is low because investors think this strong earnings performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.
View our latest analysis for Koa Shoji HoldingsLtd
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Koa Shoji HoldingsLtd.Is There Any Growth For Koa Shoji HoldingsLtd?
Koa Shoji HoldingsLtd's P/E ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the market.
Retrospectively, the last year delivered an exceptional 17% gain to the company's bottom line. As a result, it also grew EPS by 16% in total over the last three years. Therefore, it's fair to say the earnings growth recently has been respectable for the company.
Looking ahead now, EPS is anticipated to climb by 12% during the coming year according to the one analyst following the company. That's shaping up to be similar to the 10% growth forecast for the broader market.
With this information, we find it odd that Koa Shoji HoldingsLtd is trading at a P/E lower than the market. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.
The Key Takeaway
Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.
Our examination of Koa Shoji HoldingsLtd's analyst forecasts revealed that its market-matching earnings outlook isn't contributing to its P/E as much as we would have predicted. There could be some unobserved threats to earnings preventing the P/E ratio from matching the outlook. It appears some are indeed anticipating earnings instability, because these conditions should normally provide more support to the share price.
Before you take the next step, you should know about the 2 warning signs for Koa Shoji HoldingsLtd that we have uncovered.
If you're unsure about the strength of Koa Shoji HoldingsLtd's business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.
Valuation is complex, but we're here to simplify it.
Discover if Koa Shoji HoldingsLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:9273
Koa Shoji HoldingsLtd
Through its subsidiaries, imports and sells active pharmaceutical ingredients (APIs) in Japan.
Flawless balance sheet and undervalued.